Gene synthesis providers face health department oversight

File A03283 ("Gene synthesis providers face health department oversight") is before the New York Legislature and has not been decided. Latest step (March 19, 2026): advanced to third reading cal.315.

New York file A03283, before the New York Legislature. Still to be decided as of 2026-03-19.

What it does

Gene synthesis orders screened for biosecurity risks If you order synthetic DNA or RNA from a provider in NY, the company must now check your sequence against a state-approved list of potentially dangerous pathogens before fulfilling the order, delaying processing by an unspecified period.

The bigger picture

Biosecurity screening becomes standard across NY Legitimate research, diagnostics, and biotech development in New York will adopt uniform safety protocols, potentially reducing illegal or reckless DNA synthesis while adding operational overhead to smaller labs and startups.

What to watch

Rules not yet written; compliance costs unclear The bill grants the Department of Health authority to issue regulations, but those rules do not yet exist—meaning providers and buyers won't know exact screening standards, record-keeping requirements, or timelines until regulations are finalized.

How they voted

Yes (25)

No (1)

Read the official record for A03283

See everything up for a vote · This week in New York · See what we have filed with the clerk